Collegium Pharmaceutical, Inc.

符号: COLL

NASDAQ

37.51

USD

今天的市场价格

25.1608
市盈率
1.5484
PEG比率
1.20B
MRK市值
0.00%
DIV收益率

Collegium Pharmaceutical, Inc. (COLL) 财务报表

Q: 什么是 Collegium Pharmaceutical, Inc. (COLL) 总资产是多少？

Collegium Pharmaceutical, Inc. (COLL) 总资产为 .

Download

年度季度

线性对数

在图表中，您可以看到的动态默认数字 Collegium Pharmaceutical, Inc. (COLL). 的默认数据。公司收入显示 202.262 M 的平均值，即 2.308 % 增长率。整个期间的平均毛利润为 101.024 M，即 1.922 %. 平均毛利率为 0.427 %. 公司去年的净收入增长率为 -2.926 %，等于 0.539 % % 整个公司历史的平均增长率.,

年度季度

10Y 20Y 30Y 40Y

资产负债表

深入分析 Collegium Pharmaceutical, Inc. 的财务轨迹，我们可以看到其平均资产增长率。有趣的是，这一增长率为，反映了公司的高点和低点。与季度相比，这一数字调整为0. 回顾过去一年，总资产变化为 -0.026. 在流动资产领域，COLL 的报告货币为537.6. 这些资产中的很大一部分，即 310.548 是现金和短期投资。与去年的数据相比，该部分的变化率为0.788%. 公司的长期投资虽然不是其重点，但以报告货币计算的1.047（如果有的话）为1.047。这表明与上一报告期相比，-58.893% 的差异反映了公司的战略转变. 公司的债务概况显示，以报告货币计算的长期债务总额为 489.962. 这一数字表明，-0.227% 的年同比变化. 股东权益总额所体现的股东价值是以报告货币计算的 195.431. 这方面的年同比变化率为 0.003%. 深入了解公司财务信息后，会发现更多细节。应收账款净额的估值为179.525，存货估值为 32.33，商誉估值为 133.86（如有. 无形资产总额（如果有）按 421.71 估值. 应付账款和短期债务分别为 8.69 和 184.32. 债务总额为674.28，债务净额为 435.34. 其他流动负债为 264.9，加上总负债 947.88. 最后，如果存在推荐股票，则其估值为 0.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014
balance-sheet.row.cash-and-short-term-investments	1210.06	310.5	173.7	186.4	174.1	170	146.6	118.7	153.2	95.7	1.6	7.6
balance-sheet.row.short-term-investments	159.35	71.6	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.net-receivables	707.98	179.5	183.1	105.8	83.3	73	77.9	10	2.1	0	0	0
balance-sheet.row.inventory	125.38	32.3	46.5	17.4	15.6	9.6	7.8	1.8	1.3	0	0	0
balance-sheet.row.other-current-assets	51.76	0.1	16.7	0	0.1	0.1	1	0.5	0.3	0.2	2.8	0.7
balance-sheet.row.total-current-assets	2110.28	537.6	420	315.5	277.9	255.7	237.5	133.5	158.6	96.9	4.5	8.3
balance-sheet.row.property-plant-equipment-net	94.93	22	26.4	27.1	27.4	20.9	9.3	1.8	1	0.7	0.5	0.7
balance-sheet.row.goodwill	535.43	133.9	133.7	0	0	0	0	0	0	0	0	0
balance-sheet.row.intangible-assets	1900.47	421.7	567.5	268.7	335.9	29.5	44.3	0	2.1	0	0	0
balance-sheet.row.goodwill-and-intangible-assets	2435.9	555.6	701.2	268.7	335.9	29.5	44.3	0	2.1	0	0	0
balance-sheet.row.long-term-investments	3.52	1	2.5	2.5	2.5	0	0	0	0	0	0	0
balance-sheet.row.tax-assets	100.57	26.3	23.9	78	-2.5	0	0	0	0	0	0	0
balance-sheet.row.other-non-current-assets	3.89	0.8	0.1	0.1	2.7	0.2	0.2	0.3	0.3	0.1	0.1	0.1
balance-sheet.row.total-non-current-assets	2638.81	605.7	754.1	376.5	366	50.6	53.7	2.1	3.4	0.8	0.6	0.8
balance-sheet.row.other-assets	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-assets	4749.1	1143.3	1174.1	692.1	643.8	306.3	291.2	135.6	162	97.7	5.1	9
balance-sheet.row.account-payables	17.76	8.7	39.6	33.4	34.7	39.7	42.7	5.7	18	5.8	2.2	1.2
balance-sheet.row.short-term-debt	737.3	184.3	163.6	49.2	48.2	4.5	1.6	1.5	2.7	2.7	6.2	0.3
balance-sheet.row.tax-payables	21.59	7.1	4.4	3.2	1.8	0	0	0	0	0	0	0
balance-sheet.row.long-term-debt-total	2223.97	490	709.2	258.8	266.6	21.6	9.9	0	1.5	4.1	6.8	0.6
Deferred Revenue Non Current	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.deferred-tax-liabilities-non-current	0	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.other-current-liab	1015.23	264.9	66.9	147.8	108.3	153.1	143.1	24.3	-2.7	6.9	2	1.1
balance-sheet.row.total-non-current-liabilities	2223.97	490	709.2	258.8	266.6	21.6	12.2	7.2	4.2	6.9	6.9	0.8
balance-sheet.row.other-liabilities	0	0	0	0	0	0	0	-7.2	0	0	0	0
balance-sheet.row.capital-lease-obligations	29.98	7.1	8.2	8.8	9.5	10.1	0	0	0	0.1	0.1	0.1
balance-sheet.row.total-liab	3994.26	947.9	979.3	489.1	457.8	218.9	199.7	31.5	27.1	12.6	17.3	3.5
balance-sheet.row.preferred-stock	0	0	0	0	0	0	0	0	0	97.7	0	73.8
balance-sheet.row.common-stock	0.15	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.retained-earnings	-1082.85	-233.2	-281.3	-256.3	-333.1	-359.9	-337.2	-298	-223.2	-129	-101.8	-80.5
balance-sheet.row.accumulated-other-comprehensive-income-loss	-0.08	0	0	0	0	0	0	-1.7	-1.3	-1.1	-0.9	-0.7
balance-sheet.row.other-total-stockholders-equity	1837.62	428.6	476.1	459.2	519.1	447.3	428.7	403.8	359.4	117.4	90.4	13
balance-sheet.row.total-stockholders-equity	754.84	195.4	194.8	202.9	186	87.4	91.6	104.1	134.9	85.1	-12.2	5.6
balance-sheet.row.total-liabilities-and-stockholders-equity	4749.1	1143.3	1174.1	692.1	643.8	306.3	291.2	135.6	162	97.7	5.1	9
balance-sheet.row.minority-interest	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-equity	754.84	195.4	194.8	202.9	186	87.4	91.6	-	-	-	-	-
balance-sheet.row.total-liabilities-and-total-equity	4749.1	-	-	-	-	-	-	-	-	-	-	-
Total Investments	161.9	71.6	2.5	2.5	2.5	0	0	0	0	0	0	0
balance-sheet.row.total-debt	2961.26	674.3	872.8	258.8	266.6	21.6	11.5	1.5	4.1	6.8	13	1
balance-sheet.row.net-debt	1910.56	435.3	699.1	72.3	92.5	-148.4	-135.1	-117.2	-149.1	-88.9	11.4	-6.6

现金流量表

在 Collegium Pharmaceutical, Inc. 的财务状况中，自由现金流在过去一段时间内发生了显著变化，呈现出 1.237 的转变。该公司最近通过发行 9.1 扩大了股本，与上一年相比出现了2.703 的差异. 公司的投资活动产生了现金使用净额，按报告货币计算达到-70812000.000. 与上一年相比， -0.877 发生了变化. 在同一时期，公司记录了 149.26, 0 和 -301.14，这对于了解公司的投资和还款策略具有重要意义. 公司的融资活动导致使用的现金净额为0.000，同比差异为0.000. 此外，公司还将-9.1 用于向股东分红。与此同时，该公司还采取了其他财务措施，即 235.96，这也对其在此期间的现金流产生了重大影响. 这些组成部分合在一起，全面反映了公司的财务状况和现金流管理的战略方针。

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014
cash-flows.row.net-income	48.16	48.2	-25	71.5	26.8	-22.7	-39.1	-74.9	-94.2	-27.3	-17.9	-16.2
cash-flows.row.depreciation-and-amortization	149.26	149.3	138.9	68.9	61.5	15.5	110.9	0.6	0.7	0.2	0.2	0.2
cash-flows.row.deferred-income-tax	-2.15	-2.2	-8.4	-78	0	0	0	1.8	0	0	0	0.1
cash-flows.row.stock-based-compensation	27.14	27.1	22.9	24.3	21.9	16.5	13.8	7.9	5.8	2.2	0	0.1
cash-flows.row.change-in-working-capital	21.73	21.7	-12.7	13.5	-25.3	18.2	64.6	-2.5	12.7	3.3	-0.2	-0.6
cash-flows.row.account-receivables	3.59	3.6	-21.8	-22.5	-10.4	5	-68.2	-7.8	-2.1	0	0	0
cash-flows.row.inventory	14.17	14.2	48.3	-2.3	-8.3	-1.8	0.2	-0.5	-1.3	0	0	0
cash-flows.row.account-payables	5.06	5.1	-0.7	-5.8	3.8	-5.9	6.5	-3.4	5.6	1.3	1	-0.8
cash-flows.row.other-working-capital	23.77	-1.1	-38.5	44.1	-10.4	20.9	126.1	9.3	10.6	2	-1.2	0.2
cash-flows.row.other-non-cash-items	30.62	30.6	8.5	3.4	9	0.3	19.3	0	0	0	0	0
cash-flows.row.net-cash-provided-by-operating-activities	274.75	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.investments-in-property-plant-an-equipment	-0.46	-0.5	-1.6	-1.9	-373.8	-6.4	-24.4	-1	-3	-0.4	0	-0.2
cash-flows.row.acquisitions-net	-41.66	0	-572.1	0	0	0	0	0	0	0	0	0
cash-flows.row.purchases-of-investments	-92.35	-92.4	0	0	0	0	0	0	0	0	0	0
cash-flows.row.sales-maturities-of-investments	22	22	0	0	0	0	0	0	0	0	0	0
cash-flows.row.other-investing-activites	41.66	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.net-cash-used-for-investing-activites	-70.81	-70.8	-573.7	-1.9	-373.8	-6.4	-24.4	-1	-3	-0.4	0	-0.2
cash-flows.row.debt-repayment	-301.14	-301.1	-75	-50	-49	0	0	-2.7	-2.7	-1.3	-0.1	-0.1
cash-flows.row.common-stock-issued	1.84	9.1	11.8	12.7	7.3	2.9	0	34.3	137.3	72	0	0
cash-flows.row.common-stock-repurchased	-75.05	-75	-14.1	-47.9	0.8	0.8	0	1.1	24.6	69.9	0	0
cash-flows.row.dividends-paid	-57.53	-9.1	0	-12.7	-7.3	0	0	-0.7	-24.6	-24.6	0	0
cash-flows.row.other-financing-activites	291.69	236	514	8.6	334.7	-1.6	-117.1	1.4	0.9	0	12.1	12.5
cash-flows.row.net-cash-used-provided-by-financing-activities	-140.18	-140.2	436.7	-89.3	286.5	2	-117.2	33.5	135.6	116	12	12.4
cash-flows.row.effect-of-forex-changes-on-cash	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.net-change-in-cash	63.76	63.8	-12.7	12.3	6.6	23.4	27.8	-34.5	57.5	94.1	-5.9	-4.4
cash-flows.row.cash-at-end-of-period	1056.4	240	176.2	189	176.7	170	146.6	118.7	153.2	95.7	1.6	7.6
cash-flows.row.cash-at-beginning-of-period	992.64	176.2	189	176.7	170	146.6	118.8	153.2	95.7	1.6	7.6	11.9
cash-flows.row.operating-cash-flow	274.75	274.7	124.2	103.6	93.9	27.8	169.4	-67	-75.1	-21.6	-17.9	-16.5
cash-flows.row.capital-expenditure	-0.46	-0.5	-1.6	-1.9	-373.8	-6.4	-24.4	-1	-3	-0.4	0	-0.2
cash-flows.row.free-cash-flow	274.29	274.3	122.6	101.6	-279.8	21.3	145	-68	-78	-21.9	-18	-16.7

利润表行

Collegium Pharmaceutical, Inc. 的收入与上期相比变化了 0.222%。据报告, COLL 的毛利润为 326.17。该公司的营业费用为 159.21，与上年相比变化了 -9.628%. 折旧和摊销费用为 149.26，与上一会计期间相比变化了 0.074%. 营业费用报告为 159.21，显示-9.628% 的同比变化。销售和营销费用为 0, 其中 0.000% 与上年相比发生了变化。基于近期数据的EBITDA为 0，同比增长2.597%. 营业收入为 166.96，与上年相比变化了-2.597%. 净利润的变化率为 -2.926%。去年的净收入为48.16.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014
income-statement-row.row.total-revenue	566.77	566.8	463.9	276.9	310	296.7	280.4	28.5	1.7	0	0	0
income-statement-row.row.cost-of-revenue	240.6	240.6	254.4	126.3	130.2	193.7	165.7	2.6	0.2	0	0	0
income-statement-row.row.gross-profit	326.17	326.2	209.5	150.6	179.8	103	114.7	25.9	1.5	0	0	0
income-statement-row.row.gross-profit-ratio	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.research-development	0	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-general-administrative	0	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-and-marketing-expenses	0	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-expenses	0	0	0	0	0	0	0	0	-0.1	-0.3	0	0
income-statement-row.row.operating-expenses	159.21	159.2	176.2	128.4	123.6	126.8	135.4	101.3	95.6	26.9	17.7	16
income-statement-row.row.cost-and-expenses	399.81	399.8	430.6	254.7	253.8	320.4	301.1	103.9	95.8	26.9	17.7	16
income-statement-row.row.interest-income	15.62	15.6	1	0	0.2	1.9	1.7	0	0	0	0	0
income-statement-row.row.interest-expense	83.34	83.3	63.2	21	28.9	0.9	20.1	0.6	0.1	0.4	0.3	0.1
income-statement-row.row.selling-and-marketing-expenses	0	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.total-other-income-expensenet	-91.23	-23.5	75.7	43.3	32.7	1	-18.4	0.6	-0.1	-0.3	-0.3	-0.1
income-statement-row.row.ebitda-ratio-caps	0	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-operating-expenses	0	0	0	0	0	0	0	0	-0.1	-0.3	0	0
income-statement-row.row.total-operating-expenses	-91.23	-23.5	75.7	43.3	32.7	1	-18.4	0.6	-0.1	-0.3	-0.3	-0.1
income-statement-row.row.interest-expense	83.34	83.3	63.2	21	28.9	0.9	20.1	0.6	0.1	0.4	0.3	0.1
income-statement-row.row.depreciation-and-amortization	152	149.3	138.9	68.9	61.5	1.9	1.7	0.6	0.7	0.2	0.2	0.2
income-statement-row.row.ebitda-caps	331.83	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.operating-income	166.96	167	-104.6	-46.7	-5.1	-23.7	-20.7	-75.4	-94.1	-26.9	-17.7	-16
income-statement-row.row.income-before-tax	75.73	75.7	-28.8	-3.4	27.6	-22.7	-39.1	-74.9	-94.2	-27.3	-17.9	-16.2
income-statement-row.row.income-tax-expense	27.58	27.6	-3.8	-74.9	0.8	-14.6	-110.9	-1.2	0.1	-0.1	0.3	0.1
income-statement-row.row.net-income	48.16	48.2	-25	71.5	26.8	-8.1	-39.1	-74.9	-94.2	-27.3	-17.9	-16.2